What to expect in the Telix Pharmaceuticals Ltd interview process

Based on publicly available sources, Telix Pharmaceuticals Ltd. is a global, commercial-stage biopharmaceutical company specializing in radiopharmaceuticals for oncology and rare diseases, commonly referred to as theranostics. Founded in 2015 and headquartered in North Melbourne, Victoria, Australia, the company operates internationally across 21 countries—including the United States, Belgium, the United Kingdom, and Switzerland—and is publicly listed on the ASX and Nasdaq under the ticker TLX.

Workforce intelligence data indicates that Telix's global headcount grew significantly from 693 employees in 2023 to approximately 1,051 employees by March 2026. The company maintains an active hiring footprint, though data shows 153 active job postings in 2026, representing a 75.6% decline from 2025.

Executive compensation data for the fiscal year ending December 31, 2025, lists key leadership salaries in AUD, including Co-Founder, MD, and Group CEO Dr. Christian P. Behrenbruch at approximately $991.63k; Group CFO Mr. Darren Smith at $911.83k; Group COO Mr. Darren Patti at $708.49k; and Group CMO Dr. David N. Cade at $679.38k. ESG transparency evaluations assign Telix a UN SDG ESG Transparency Score of 6.7, reflecting an environmental score of 4.0, a social score of 8.0, and a governance score of 8.0. The company's core commercial engine is driven largely by US sales of its lead imaging agent, Illuccix, alongside a broader clinical pipeline targeting urologic, neuro-, and musculoskeletal oncology.